Native GLP-1 has a short half-life, but its longer-acting analogues have been used successfully in the treatment of obesity and T2D [65], and GLP-1 has been shown to decrease blood glucose in human subjects with T2D (reviewed in [66]). The gene discussed is GCG; the disease is type 2 diabetes mellitus.